Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,21400Cr 166.85Cr 149.74Cr 138.27Cr 125.38Cr 234.34Cr 16TCr 237.22Cr 1.66TCr 658.36Cr 8.31TCr 626.29Cr 612.89Cr 26TCr P/E 2026 *
-62.9x
P/E 2027 * -64.7x
Enterprise Value 2,21400Cr 166.85Cr 149.74Cr 138.27Cr 125.38Cr 234.34Cr 16TCr 237.22Cr 1.66TCr 658.36Cr 8.31TCr 626.29Cr 612.89Cr 26TCr EV / Sales 2026 *
277x
EV / Sales 2027 * 201x
Free-Float
84.88%
Yield 2026 *
-
Yield 2027 * -
13/10 Roche Licenses Obesity Therapy From China's Rona in Up to $1.2 Billion Deal DJ
14/08 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
30/07 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
08/07 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
29/06 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
04/06 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
01/06 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
15/05 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01/04 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
16/03 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
08/02 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
02/12 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
14/11 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day+7.40%
1 week-0.31%
Current month-5.07%
1 month-5.26%
3 months-14.42%
6 months-50.48%
Current year-30.70%
1 week 86,600
Extreme 86600
1,09,600
1 month 84,300
Extreme 84300
1,26,900
Current year 84,300
Extreme 84300
2,17,000
1 year 84,300
Extreme 84300
2,17,000
3 years 8,280
Extreme 8280
2,17,000
5 years 8,280
Extreme 8280
2,17,000
10 years 8,280
Extreme 8280
2,17,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 61 19/03/2019
Director/Board Member 55 19/03/2019
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap. Importance
28/02/25 Exercice

Director

30,000 0.1625%
28/02/25 Exercice

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
+7.40%-0.31%-2.41%+634.34% 155.36Cr
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+2.55%+1.91%+12.52%+83.26% 5.45TCr
-0.87%+0.93%+10.38%+102.05% 5.36TCr
+3.12%+1.64%+28.90%+58.71% 4.48TCr
+2.53%-2.84%+18.50%+101.21% 4.16TCr
+0.99%-3.24%+223.16%+924.41% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+28.29%+43.78%+101.71%+89.20% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +4.90%-1.16%+46.23%+209.63% 3.82TCr
Weighted average by Cap. +3.37%-0.32%+47.11%+163.26%

Financials

2026 *2027 *
Net sales 800Cr 60.3L 54.12L 49.97L 45.31L 84.69L 57Cr 85.73L 5.99Cr 2.38Cr 30Cr 2.26Cr 2.21Cr 95Cr 1.1TCr 82.91L 74.41L 68.71L 62.31L 1.16Cr 79Cr 1.18Cr 8.24Cr 3.27Cr 41Cr 3.11Cr 3.05Cr 130.9Cr
Net income -3.1TCr -2.34Cr -2.1Cr -1.94Cr -1.76Cr -3.28Cr -221.94Cr -3.32Cr -23Cr -9.22Cr -116.33Cr -8.77Cr -8.58Cr -368.9Cr -3TCr -2.26Cr -2.03Cr -1.87Cr -1.7Cr -3.18Cr -214.78Cr -3.21Cr -22Cr -8.92Cr -112.58Cr -8.49Cr -8.31Cr -357Cr
Net Debt - -
Projected Income Statement - Annual - OliX Pharmaceuticals, Inc
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
81
Date Price Change Volume
28/26/28 ₩97,300.00 +7.40% 2,24,874
27/26/27 ₩90,600.00 -5.72% 2,60,316
26/26/26 ₩96,100.00 -6.97% 1,03,794
23/26/23 ₩1,03,300.00 -2.18% 1,23,994
22/26/22 ₩1,05,600.00 -1.22% 1,27,964
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - OliX Pharmaceuticals, Inc

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - OliX Pharmaceuticals, Inc
  1. Stock Market
  2. Stocks
  3. A226950 Stock